APREMILAST MEPHA cpr pellic 10mgx4/20x4/30x19 pce

7680694980012 CH-69498 L04AA32 07.15.0.

Active substances:

Apremilastum

No images available

Details

Product number
6949801
CPT
-
Packaging group
4+4+19
Unit
Tablette(n)
Composition
I) 10 mg: apremilastum 10 mg, lactosum monohydricum 40 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.27 mg, magnesii stearas, Überzug: hypromellosum, E 171, macrogolum 3350, E 172 (rubrum), pro compresso obducto. II) 20 mg: apremilastum 20 mg, lactosum monohydricum 80 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.54 mg, magnesii stearas, Überzug: hypromellosum, E 171, E 172 (flavum), macrogolum 3350, E 172 (rubrum), pro compresso obducto. III) 30 mg: apremilastum 30 mg, lactosum monohydricum 120 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.81 mg, magnesii stearas, Überzug: hypromellosum, E 171, macrogolum 3350, E 172 (rubrum), pro compresso obducto.

Articles (1)

Apremilast-Mepha 10 mg, 20 mg, 30 mg Filmtabletten
Filmtabletten
4+4+19
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
04/08/2026
Professional SmPC
Français
04/08/2026
Professional SmPC
Italien
04/08/2026
Patient information leaflet
Allemand
02/09/2025
Patient information leaflet
Français
02/09/2025
Patient information leaflet
Italien
02/09/2025

Detailed composition

Substance Quantity Type Category
apremilastum
20.0 MG Substance Wirkstoff (Principe actif)
apremilastum
30.0 MG Substance Wirkstoff (Principe actif)
apremilastum
10.0 MG Substance Wirkstoff (Principe actif)
lactosum monohydricum
80.0 MG Substance HBESI
lactosum monohydricum
40.0 MG Substance HBESI
lactosum monohydricum
120.0 MG Substance HBESI
cellulosum microcristallinum
- Substance HNIDK
cellulosum microcristallinum
- Substance HNIDK
cellulosum microcristallinum
- Substance HNIDK
carmellosum natricum conexum
- Substance HNIDK
carmellosum natricum conexum
- Substance HNIDK
carmellosum natricum conexum
- Substance HNIDK
natrium
0.54 MG Substance HBESI
natrium
0.81 MG Substance HBESI
natrium
0.27 MG Substance HBESI
magnesii stearas
- Substance HNIDK
magnesii stearas
- Substance HNIDK
magnesii stearas
- Substance HNIDK
hypromellosum
- Substance HNIDK
hypromellosum
- Substance HNIDK
hypromellosum
- Substance HNIDK
E 171
- Substance FNIDK
E 171
- Substance FNIDK
E 171
- Substance FNIDK
E 172 (flavum)
- Substance FTODK
macrogolum 3350
- Substance HNIDK
macrogolum 3350
- Substance HNIDK
E 172 (rubrum)
- Substance FTODK
E 172 (rubrum)
- Substance FTODK
macrogolum 3350
- Substance HNIDK
E 172 (rubrum)
- Substance FTODK

Reimbursement information

Public price
CHF 161.60
Specialties list
Yes
Generic
Yes

Reimbursement limitation

SL addition date: 01/09/2025

Authorization holder

Mepha Pharma AG

4051 Basel

Authorization information

Swissmedic authorization number
69498
Drug name
Apremilast-Mepha, Filmtabletten
Galenic form
FILM
ATC Code
L04AA32
Authorization status
Z
Dispensation category
B
First authorization
22/07/2025
Authorization expiration date
21/07/2030
IT number
07.15.0.
Domain
Human medicine
Field of application
Aktive Psoriasis-Arthritis und mittelschwere bis schwere Plaque-Psoriasis

Packaging details

Description (FR)
APREMILAST MEPHA cpr pellic 10mgx4/20x4/30x19 pce
Description (DE)
APREMILAST MEPHA Filmtabl 10mgx4/20x4/30x19 Stk
Market launch
19/08/2025
Narcotic (BTM)
No

Original drug

Otezla, Filmtabletten
GTIN: 7680653460036
CHF 334.85
View original

Other packaging sizes

APREMILAST MEPHA cpr pellic 30 mg 56 pce
56 TABL
GTIN: 7680694980029
View
Buy us a coffee Explore the data